KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Non-Current Debt (2016 - 2026)

Gsk has reported Non-Current Debt over the past 18 years, most recently at -$18.9 billion for Q1 2026.

  • For Q1 2026, Non-Current Debt rose 8.96% year-over-year to -$18.9 billion; the TTM value through Mar 2026 reached -$18.9 billion, up 8.96%, while the annual FY2025 figure was -$19.6 billion, 204.4% down from the prior year.
  • Non-Current Debt for Q1 2026 was -$18.9 billion at Gsk, up from -$19.6 billion in the prior quarter.
  • Over five years, Non-Current Debt peaked at $20.0 billion in Q4 2022 and troughed at -$23.7 billion in Q2 2022.
  • A 5-year average of -$12.6 billion and a median of -$19.5 billion in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: soared 60.47% in 2022 and later plummeted 204.4% in 2025.
  • Year by year, Non-Current Debt stood at $20.0 billion in 2022, then decreased by 5.55% to $18.9 billion in 2023, then dropped by 0.7% to $18.7 billion in 2024, then plummeted by 204.4% to -$19.6 billion in 2025, then grew by 3.44% to -$18.9 billion in 2026.
  • Business Quant data shows Non-Current Debt for GSK at -$18.9 billion in Q1 2026, -$19.6 billion in Q4 2025, and -$20.1 billion in Q3 2025.